GO:0120190 negative regulation of bile acid secretion: Regulatory Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0120190 describes the biological process that reduces or prevents the secretion of bile acids from cells, a critical homeostatic brake on bile acid flux.
• The ileal bile acid transport system undergoes negative feedback regulation, so that excess bile acids suppress their own uptake and secretion.
• The nuclear receptor FXR (NR1H4) is a central mediator of negative regulation of bile acid secretion, sensing bile acids and repressing transport and synthesis genes.
• Gut microbiota modify bile acids and thereby tune FXR signaling, indirectly controlling the negative regulation of bile acid secretion.
• Loss of negative regulation contributes to cholestasis, cholesterol gallstones, and sepsis-associated inflammation.
• CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of genes in this process.
Description
GO:0120190, negative regulation of bile acid secretion, is a biological process that dampens or prevents the release of bile acids from cells into the bile canaliculus, sinusoidal blood, or intestinal lumen. Bile acids are detergents that facilitate lipid absorption, but their accumulation is cytotoxic; therefore, negative regulation of bile acid secretion is a protective homeostatic mechanism. The process is best understood in the ileum, where the ileal bile acid transport system is subject to negative feedback regulation by bile acids themselves. This feedback prevents excessive bile acid flux and maintains enterohepatic circulation. Researchers study GO:0120190 because its failure is linked to cholestasis, gallstone disease, and inflammation-driven pathologies. The process intersects with nuclear receptor signaling, especially FXR, and with microbial bile acid metabolism. Understanding negative regulation of bile acid secretion at the molecular level is essential for developing therapeutics that modulate bile acid pools without causing toxicity.
negative regulation of bile acid secretion At A Glance
| GO ID | GO:0120190 |
|---|---|
| GO term | negative regulation of bile acid secretion |
| Ontology | biological_process |
| Synonym | None listed in QuickGO |
| Major function | Reduces or prevents the secretion of bile acids from cells, protecting against bile acid toxicity and maintaining bile acid homeostasis. |
| Key regulator | FXR (NR1H4) signaling is a major mediator of negative feedback on bile acid transport and synthesis. |
| Tissue context | Ileum, liver, and intestine are primary sites where negative regulation of bile acid secretion operates. |
| Disease relevance | Cholestasis, cholesterol gallstones, and sepsis-associated inflammation involve impaired negative regulation. |
| Research methods | CRISPR knockout, point mutation, knock-in, overexpression, and bile acid flux assays are used to study this process. |
What Is GO:0120190?
In our own words, negative regulation of bile acid secretion (GO:0120190) is any process that reduces the frequency, rate, or extent of bile acid secretion. Bile acid secretion is the directed movement of bile acids out of a cell, and negative regulation of this process acts as a brake on bile acid release. This regulation can occur through transcriptional repression of transport proteins, post-translational modification of transporters, or feedback signaling from bile acid sensors such as FXR. The term is a biological process and is distinct from positive regulation of bile acid secretion.
Why Is negative regulation of bile acid secretion Important in Cell Biology?
Negative regulation of bile acid secretion is important because bile acids are powerful detergents that can damage membranes and trigger inflammation when their secretion is not properly restrained. This process maintains bile acid homeostasis, preventing cholestatic injury and limiting pathological inflammation. It also influences metabolic signaling through FXR and TGR5, affecting glucose and lipid metabolism. Dysregulation of this process contributes to cholesterol gallstone formation and colorectal cancer progression. Therefore, understanding negative regulation of bile acid secretion provides mechanistic insight into liver, metabolic, and gastrointestinal diseases.
• Prevents bile acid toxicity by limiting excessive secretion into bile and intestine.
• Maintains enterohepatic circulation and bile acid pool size.
• Mediates FXR-dependent feedback that represses bile acid synthesis and transport.
• Protects against cholestasis-associated sepsis and inflammation.
• Influences cholesterol gallstone formation through FXR signaling.
• Modulates gut microbiota-host bile acid crosstalk.
• Affects systemic glucose control via intestinal FXR-TGR5 crosstalk.
• Contributes to colorectal cancer biology by shaping bile acid pools that suppress CD8+ T cells.
• Provides therapeutic targets for metabolic and liver diseases.
• Enables causal gene testing using CRISPR models.
What Happens During negative regulation of bile acid secretion?
Bile acid sensing by FXR
In simple terms: Bile acids act like keys that turn on a sensor called FXR, which then tells the cell to stop making and moving bile acids.
The nuclear receptor FXR (NR1H4) senses elevated intracellular bile acids and initiates a transcriptional program that negatively regulates bile acid secretion. FXR activation in the ileum and liver induces repressors such as SHP and FGF19, which inhibit bile acid synthesis and transport. This feedback loop is a primary mechanism of negative regulation of bile acid secretion.
Negative feedback on ileal bile acid transport
In simple terms: When too much bile acid is present, the intestine reduces its ability to take up and secrete more bile acids.
The ileal bile acid transport system is subject to negative feedback regulation in rodents, where bile acid exposure downregulates transport activity. This feedback reduces the secretion of bile acids from enterocytes and limits their flux into the portal circulation. The process is a classic example of negative regulation of bile acid secretion.
Microbial modification of bile acids
In simple terms: Gut bacteria change bile acids into forms that can either activate or block FXR, thereby tuning the brake on bile acid secretion.
Gut microbiota regulate bile acid metabolism by reducing levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist, which alters FXR signaling and downstream bile acid secretion. Host metabolism balances microbial regulation of bile acid signaling, adding another layer of control over negative regulation of bile acid secretion. These interactions show that the microbiota is an upstream modulator of this process.
Inflammatory and immune modulation
In simple terms: Inflammation can interfere with the brake on bile acid secretion, and immune receptors can help restore it.
FXR regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis, linking bile acid signaling to inflammation. TREM-2 acts as a negative regulator of inflammation in cholestasis, protecting against bile acid-induced injury. These findings indicate that immune and inflammatory pathways intersect with negative regulation of bile acid secretion.
Metabolic and thermogenic crosstalk
In simple terms: Bile acid signals from the intestine can affect fat burning and glucose control, showing that this brake has whole-body effects.
Functional changes in gastric bypass microbiota reactivate thermogenic adipose tissue and systemic glucose control via intestinal FXR-TGR5 crosstalk in diet-induced obesity. This demonstrates that negative regulation of bile acid secretion is integrated with systemic metabolic regulation. The process therefore extends beyond the liver and intestine to influence energy homeostasis.
Key Genes Involved in GO:0120190 negative regulation of bile acid secretion
The following genes and proteins are experimentally implicated in negative regulation of bile acid secretion or its upstream signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NR1H4 (FXR) | Nuclear receptor that senses bile acids and induces negative feedback on bile acid synthesis and transport | Central mediator of negative regulation of bile acid secretion; target for cholestasis and gallstone studies |
| FGF19 | Intestinal hormone induced by FXR that represses bile acid synthesis | Readout of FXR activation and negative feedback in ileum |
| SHP (NR0B2) | Transcriptional repressor induced by FXR that inhibits bile acid synthesis genes | Mediator of FXR-dependent negative regulation |
| ASBT (SLC10A2) | Ileal bile acid transporter subject to negative feedback | Key target of negative regulation of bile acid secretion in ileum |
| IBABP (FABP6) | Intracellular bile acid binding protein involved in ileal transport | Component of the ileal bile acid transport system under feedback control |
| OSTα/OSTβ | Basolateral bile acid efflux transporter | Efflux step that can be negatively regulated to limit bile acid secretion |
| NLRP3 | Inflammasome activated during cholestasis-associated sepsis | Links bile acid signaling to inflammation and sepsis |
| TREM-2 | Negative regulator of inflammation in cholestasis | Protective role against bile acid-induced liver injury |
| TGR5 (GPBAR1) | Bile acid receptor mediating metabolic crosstalk | Mediates intestinal FXR-TGR5 crosstalk in obesity |
| CYP7A1 | Rate-limiting enzyme of bile acid synthesis | Repressed by FXR-FGF19 feedback, indirectly reducing bile acid secretion |
| CYP8B1 | Bile acid synthesis enzyme | Modulated by FXR signaling in gallstone studies |
| BSEP (ABCB11) | Canalicular bile acid efflux pump | Efflux transporter whose regulation affects bile acid secretion |
| MRP2 (ABCC2) | Canalicular organic anion transporter | Contributes to bile acid flux and cholestasis |
| NTCP (SLC10A1) | Sinusoidal bile acid uptake transporter | Uptake step influencing intracellular bile acid levels |
| IL-1β | Inflammatory cytokine downstream of NLRP3 | Mediates cholestasis-associated sepsis |
| TNF-α | Inflammatory cytokine in cholestasis | Marker of inflammation in bile acid injury |
| CD8+ T cells | Effector immune cells suppressed by microbiota-modified bile acids | Link bile acid pools to colorectal cancer immunity |
| Tauro-beta-muricholic acid (T-βMCA) | Natural FXR antagonist modified by microbiota | Microbial regulator of FXR and bile acid secretion |
How Is negative regulation of bile acid secretion Regulated?
Negative regulation of bile acid secretion is itself regulated at multiple levels. FXR activation induces FGF19 and SHP, which repress bile acid synthesis and transport, forming a negative feedback loop. The ileal bile acid transport system is downregulated by bile acid exposure, providing direct feedback inhibition. Gut microbiota modulate this process by altering the abundance of FXR antagonists such as tauro-beta-muricholic acid. Host metabolism balances microbial regulation of bile acid signaling, ensuring that the negative regulation is context-dependent. Inflammatory signals, including NLRP3 inflammasome activation, can disrupt this regulation during cholestasis. TREM-2 acts as a negative regulator of inflammation that protects against cholestatic injury. Metabolic crosstalk through TGR5 further integrates bile acid signaling with systemic energy control.
negative regulation of bile acid secretion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NR1H4 (FXR) | Cholestasis, cholesterol gallstones | Liver-specific FXR knockout mouse |
| NLRP3 | Cholestasis-associated sepsis | NLRP3 knockout mouse with bile duct ligation |
| TREM-2 | Cholestatic liver injury | TREM-2 knockout mouse |
| ASBT (SLC10A2) | Ileal bile acid malabsorption | Intestinal ASBT knockout mouse |
| CD8+ T cells | Colorectal cancer | Bile acid-treated tumor models |
Cholestasis and sepsis
Impaired negative regulation of bile acid secretion leads to bile acid accumulation and cholestatic liver injury. FXR regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis, where bile acid signaling drives excessive inflammation. TREM-2 protects against cholestasis by acting as a negative regulator of inflammation, highlighting the importance of braking mechanisms.
Cholesterol gallstones
FXR signaling-mediated bile acid metabolism is critical for alleviation of cholesterol gallstones by Lactobacillus strains. Negative regulation of bile acid secretion helps maintain cholesterol solubility in bile, and its failure promotes gallstone formation. This links the process to a common gastrointestinal disease.
Colorectal cancer
Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8+ T cell effector functions. Because negative regulation of bile acid secretion shapes the bile acid pool, its dysregulation may influence anti-tumor immunity. This positions the process as a potential modifier of cancer progression.
Metabolic disease and obesity
Functional changes in gastric bypass microbiota reactivate thermogenic adipose tissue and systemic glucose control via intestinal FXR-TGR5 crosstalk in diet-induced obesity. Negative regulation of bile acid secretion is therefore connected to systemic metabolic control. Host metabolism balances microbial regulation of bile acid signaling, with implications for obesity and diabetes.
From negative regulation of bile acid secretion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FXR mediate negative regulation of bile acid secretion? | FXR knockout (KO) cell line and mouse |
| Does a point mutation in ASBT alter feedback regulation? | ASBT point-mutation knock-in cell model |
| Can a tagged transporter be tracked during feedback? | Tagged knock-in of OSTα/OSTβ |
| Does overexpression of SHP repress bile acid secretion? | SHP overexpression cell model |
| Does TREM-2 protect against cholestasis? | TREM-2 KO and overexpression models |
| Does microbiota-modified bile acid affect FXR signaling? | Gnotobiotic and FXR reporter models |
How to Study the negative regulation of bile acid secretion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Bile acid flux assay | Secretion and uptake of bile acids | Ileal and hepatic cell monolayers |
| FXR luciferase reporter | FXR transcriptional activity | Drug and gene screening |
| RNA-seq | Global transcriptional changes | Cholestasis and gallstone models |
| qPCR | Expression of transporters and enzymes | Validation of feedback genes |
| 16S rRNA sequencing | Microbial community composition | Microbiota-bile acid studies |
| Bile acid metabolomics | Bile acid species and abundance | FXR antagonist identification |
| Immunoblotting | Protein levels of transporters | Feedback regulation studies |
| Immunofluorescence | Subcellular localization of transporters | Polarized cell transport studies |
Bile acid flux assays
Bile acid secretion and uptake can be measured using radiolabeled or fluorescent bile acid analogs in polarized cell monolayers. These assays quantify the functional output of negative regulation of bile acid secretion. They are typically applied to ileal and hepatic cell models.
Transcriptional reporter assays
FXR-responsive luciferase reporters measure the activation of negative feedback pathways that repress bile acid transport genes. Such assays are used to test whether a gene or treatment enhances negative regulation of bile acid secretion. They provide a sensitive readout of FXR signaling.
RNA-seq and qPCR
RNA-seq and qPCR quantify expression of bile acid transporters and synthesis enzymes after experimental manipulation. These methods reveal transcriptional changes underlying negative regulation of bile acid secretion. They are widely used in cholestasis and gallstone studies.
Microbiome and metabolomics
16S sequencing and bile acid metabolomics identify microbial taxa and metabolites that modulate FXR signaling. These approaches link gut microbiota to negative regulation of bile acid secretion. They are applied in obesity and metabolic studies.
How CRISPR Can Be Used to Study GO:0120190 negative regulation of bile acid secretion
Knockout
CRISPR knockout of FXR, ASBT, or TREM-2 enables loss-of-function studies of negative regulation of bile acid secretion. Knockout models reveal whether a gene is required for feedback inhibition of bile acid transport. They are widely used in cholestasis and gallstone research.
Point Mutation
Point mutations in transporter or receptor genes can dissect specific residues required for feedback regulation. CRISPR point-mutation models test whether a single amino acid change alters negative regulation of bile acid secretion. Such models are valuable for mechanistic studies of ASBT and FXR.
Knock-in
Knock-in of tags or reporters into endogenous loci allows tracking of transporter dynamics during negative regulation. Tagged knock-in models can visualize OSTα/OSTβ trafficking in live cells. They provide spatial and temporal resolution of the process.
Overexpression
Overexpression of SHP, FGF19, or TREM-2 can enhance negative regulation of bile acid secretion and protect against cholestasis. CRISPR activation or cDNA overexpression models test gain-of-function effects. These models are useful for identifying therapeutic targets.
How EDITGENE Supports negative regulation of bile acid secretion Research
Researchers studying negative regulation of bile acid secretion-related genes often need to determine whether a candidate gene is causally involved in feedback inhibition of bile acid transport, or whether it merely correlates with the phenotype. EDITGENE provides publication-ready CRISPR models that enable precise genetic perturbation of FXR, ASBT, TREM-2, and other pathway components. By combining knockout, point-mutation, knock-in, and overexpression strategies with functional bile acid flux assays, EDITGENE helps laboratories move from association to causation in bile acid research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of bile acid secretion research.
Frequently Asked Questions About negative regulation of bile acid secretion
What is negative regulation of bile acid secretion (GO:0120190)?
It is a biological process that reduces or prevents the secretion of bile acids from cells, protecting against bile acid toxicity and maintaining homeostasis.
What genes are involved in negative regulation of bile acid secretion?
Key genes include NR1H4 (FXR), FGF19, SHP, ASBT (SLC10A2), OSTα/OSTβ, TREM-2, and NLRP3.
How does FXR regulate bile acid secretion?
FXR senses bile acids and induces FGF19 and SHP, which repress bile acid synthesis and transport, thereby negatively regulating secretion.
What is the role of gut microbiota in bile acid secretion?
Gut microbiota modify bile acids and reduce FXR antagonists such as tauro-beta-muricholic acid, thereby tuning negative regulation of bile acid secretion.
Which diseases are linked to impaired negative regulation of bile acid secretion?
Cholestasis, cholesterol gallstones, sepsis-associated inflammation, and colorectal cancer have been linked to dysregulated bile acid secretion.
How can I study negative regulation of bile acid secretion in the lab?
Common methods include bile acid flux assays, FXR reporter assays, RNA-seq, qPCR, and CRISPR knockout models.
What is the ileal bile acid transport system?
It is the transport machinery in the ileum that mediates bile acid uptake and secretion, and it is subject to negative feedback regulation.
Does TREM-2 protect against cholestasis?
Yes, TREM-2 acts as a negative regulator of inflammation in cholestasis, protecting against bile acid-induced injury.
Can CRISPR be used to study bile acid secretion?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are used to test causal roles of genes in this process.
What is the role of NLRP3 in cholestasis-associated sepsis?
FXR regulation of the NLRP3 inflammasome underlies cholestasis-associated sepsis, linking bile acid signaling to inflammation.
Conclusion
Negative regulation of bile acid secretion (GO:0120190) is a vital homeostatic process that restrains bile acid release and protects against cholestatic and inflammatory injury. Its molecular basis centers on FXR signaling, ileal transport feedback, and microbial bile acid modification. Dysregulation of this process contributes to gallstones, sepsis, and colorectal cancer, making it a compelling therapeutic target. CRISPR-based models from EDITGENE enable precise causal interrogation of the genes that control this process, supporting the development of new interventions for bile acid-related diseases.
References
- 1. Hao H et al.. 2017. Farnesoid X Receptor Regulation of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis.. Cell Metab 25(4):856-867.e5 PMID: 28380377
- 2. Sayin SI et al.. 2013. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist.. Cell Metab 17(2):225-35 PMID: 23395169
- 3. Cong J et al.. 2024. Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8(+) T cell effector functions.. Immunity 57(4):876-889.e11 PMID: 38479384
- 4. Won TH et al.. 2025. Host metabolism balances microbial regulation of bile acid signalling.. Nature 638(8049):216-224 PMID: 39779854
- 5. Ye X et al.. 2022. FXR Signaling-Mediated Bile Acid Metabolism Is Critical for Alleviation of Cholesterol Gallstones by Lactobacillus Strains.. Microbiol Spectr 10(5):e0051822 PMID: 36036629
- 6. Lillienau J et al.. 1993. Negative feedback regulation of the ileal bile acid transport system in rodents.. Gastroenterology 104(1):38-46 PMID: 8419260
- 7. Münzker J et al.. 2022. Functional changes of the gastric bypass microbiota reactivate thermogenic adipose tissue and systemic glucose control via intestinal FXR-TGR5 crosstalk in diet-induced obesity.. Microbiome 10(1):96 PMID: 35739571
- 8. Labiano I et al.. 2022. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation.. J Hepatol 77(4):991-1004 PMID: 35750136
